Target Information

Target General Infomation
Target ID
T87108
Former ID
TTDNC00477
Target Name
Mesothelin-ADC
Gene Name
MSLN
Synonyms
CAK1 antigen; MPF; Mesothelin; Mesothelin, cleaved form; Prepromegakaryocytepotentiating factor; MSLN
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Mesothelioma [ICD9: 163; ICD10: C45]
Mesothelioma; Metastatic pancreatic cancer [ICD9:163, 185; ICD10: C45, C61]
Ovarian cancer [ICD9: 183; ICD10: C56]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Membrane-anchored forms may play a role in cellular adhesion. .
BioChemical Class
Mesothelin
UniProt ID
Q13421
Sequence
MALPTARPLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISS
LSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPL
DLLLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEA
DVRALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTW
SVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKT
ACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELY
PQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQAPRRPLPQVA
TLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQ
LDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVL
PLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLS
MQEALSGTPCLLGPGPVLTVLALLLASTLA
Drugs and Mode of Action
Drug(s) CRS-207 Drug Info Phase 2 Mesothelioma; Metastatic pancreatic cancer [524918]
MORAb-009 Drug Info Phase 2 Mesothelioma [522179], [542714]
BAY 94-9343 Drug Info Phase 1 Solid tumours [523636]
RG7882 Drug Info Phase 1 Ovarian cancer [548800]
SS1(dsFv)-PE38 Drug Info Discontinued in Phase 1 Cancer [547030]
Modulator BAY 94-9343 Drug Info [550479]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
NetPath Pathway TCR Signaling Pathway
References
Ref 522179ClinicalTrials.gov (NCT00570713) An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer. U.S. National Institutes of Health.
Ref 523636ClinicalTrials.gov (NCT01439152) Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
Ref 524918ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 542714(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7750).
Ref 547030Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012262)
Ref 548800Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028960)
Ref 529110Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53. Epub 2007 Oct 22.
Ref 532964Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
Ref 533108Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
Ref 550348Molecular Imaging As a Tool for Drug Development and Trial Design. JCO July 13, 2015 JCO.2015.61.6425
Ref 550415National Cancer Institute Drug Dictionary (drug id 543500).
Ref 550479National Cancer Institute Drug Dictionary (drug id 712853).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.